Kageyama Goichi
Rinsho Byori. 2015 May;63(5):570-9.
Osteoporosis is a common and under-diagnosed disease characterized by the systemic impairment and structural deterioration of bone tissue, leading to bone fragility and an increased risk of fractures of the hip, spine, and wrist. Recent progress in osteoporosis revealed new information on its pathogenesis, the relative risks of fragility fractures, and new treatment measures. In the wake of progress in osteoporosis research, the Japanese Society for Bone and Mineral Research (JSBMR) and Japan Osteoporosis Society Joint Review Committee revised the diagnostic criteria for primary osteoporosis, aimed at obtaining international consensus on the new findings, in 2012. The JSBMR also published guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis in that year. Then, the JSBMR revised the guidelines on the management and treatment of glucocorticoid-induced osteoporosis in 2014. This article focuses on the diagnosis and pharmacological treatment of osteoporosis, with an overview of the Japanese guidelines.
骨质疏松症是一种常见但诊断不足的疾病,其特征是骨组织的系统性损伤和结构恶化,导致骨骼脆弱,髋部、脊柱和腕部骨折风险增加。骨质疏松症的最新进展揭示了有关其发病机制、脆性骨折相对风险的新信息以及新的治疗措施。随着骨质疏松症研究的进展,日本骨与矿物质研究学会(JSBMR)和日本骨质疏松症学会联合审查委员会于2012年修订了原发性骨质疏松症的诊断标准,旨在就新发现达成国际共识。同年,JSBMR还发布了骨代谢标志物在骨质疏松症诊断和治疗中的应用指南。然后,JSBMR在2014年修订了糖皮质激素诱导的骨质疏松症的管理和治疗指南。本文重点关注骨质疏松症的诊断和药物治疗,并概述日本指南。